Patent Application
20100160349
The present invention concerns a novel group of compounds, their use as a medicine, their use for the manufacture of a medicament for the treatment of a disease mediated through glycogen synthase kinase 3 (GSK3), in particular glycogen synthase kinase 3α and 3β; processes for their preparation and pharmaceutical compositions comprising them.
WO 00/62778 describes cyclic protein tyrosine kinase inhibitors. In particular, it discloses thiazolyl derivatives comprising a bicyclic ring system.
WO 01/44246 describes bicyclic pyrimidine and pyridine based compounds having GSK3 inhibiting activity.
WO 99/65897 describes pyrimidine and pyridine based compounds having GSK3 inhibiting activity.
WO 02/04450 describes purine derivatives having the activity of either inhibiting the formation of amyloid beta or stimulating the formation of sbeta-amyloid precursor protein.
WO 02/50073 describes pyrazolo[3,4-c]pyridines as GSK-3 inhibitors.
WO 2004/018473 relates to di- and trisubstituted 8-aza purine derivatives as cyclin-dependent kinase inhibitors.
JP 59062594 describes 3,5-disubstituted triazolopyrimidine compounds.
The present invention relates to compounds, which are distinguishable from the prior art in structure, pharmacological activity, potency, selectivity, solubility, permeability, metabolic stability.
The present invention concerns a compound of formula (I)
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein
—CH2—CH2—CH2— (b-1);
—CH2—CH2—CH2—CH2— (b-2);
—X1—CH2—CH2—(CH2)n— (b-3);
—X1—CH2—(CH2)n—X1— (b-4);
—X1—(CH2)n′—CH═CH— (b-5);
—CH═N—X1— (b-6);
The present invention also relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of a disease mediated through GSK3 wherein the compound of formula (I) is a compound having the following formula
a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein
—CH2—CH2—CH2— (b-1);
—CH2—CH2—CH2—CH2— (b-2);
—X1—CH2—CH2—(CH2)n— (b-3);
—X1—CH2—(CH2)n—X1— (b-4);
—X1—(CH2)n′—CH═CH— (b-5);
—CH═N—X1— (b-6);
As used herein C1-2alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 2 carbon atoms such as methyl, ethyl; C1-3alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 3 carbon atoms such as such as the groups defined for C1-2alkyl and propyl, 1-methylethyl; C1-4alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as the groups defined for C1-3alkyl and butyl; C1-6alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the groups defined for C1-4alkyl and pentyl, hexyl, 2-methylbutyl and the like; C2-4alkenyl as a group or part of a group defines straight and branched chain hydrocarbon radicals having from 2 to 4 carbon atoms and containing a double bond such as ethenyl, propenyl, butenyl and the like; C2-6alkenyl as a group or part of a group defines straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms and containing a double bond such as the groups defined for C2-4alkenyl and pentenyl, hexenyl and the like; C2-6alkynyl as a group or part of a group defines straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms and containing a triple bond such as such as ethynyl, propynyl, butynyl, pentynyl, hexynyl and the like; C3-7cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; a 4, 5, 6- or 7-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N comprises saturated, partially saturated or aromatic 4, 5, 6- or 7-membered monocyclic heterocycles containing at least one heteroatom selected from O, N or S; saturated heterocycles are heterocycles containing only single bonds; partially saturated heterocycles are heterocycles containing at least one double bond provided that the ring system is not an aromatic ring system; the term aromatic is well known to a person skilled in the art and designates cyclically conjugated systems of 4n′+2 electrons, that is with 6, 10, 14 etc. π-electrons (rule of Hückel; n′ being 1, 2, 3 etc.).
Particular examples of 4, 5, 6- or 7-membered saturated monocyclic heterocycles are azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, thiazolidinyl, tetrahydrothienyl, dihydrooxazolyl, isothiazolidinyl, isoxazolidinyl, oxadiazolidinyl, triazolidinyl, thiadiazolidinyl, pyrazolidinyl, piperidinyl, hexahydropyrimidinyl, hexahydropyridazinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, homopiperidinyl (azepanyl), [1,3]diazepanyl, homopiperazinyl ([1,4]diazepanyl), [1,2]diazepanyl, oxepanyl, dioxepanyl.
Particular examples of 5- or 6-membered partially saturated heterocycles are pyrrolinyl, imidazolinyl, pyrazolinyl and the like.
Particular examples of 4, 5, 6- or 7-membered aromatic monocyclic heterocycles are pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl.
As used herein before, the term (═O) forms a carbonyl moiety when attached to a carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom.
The term halo is generic to fluoro, chloro, bromo and iodo. As used in the foregoing and hereinafter, polyhaloC1-4alkyl and polyhaloC1-6alkyl as a group or part of a group are defined as mono- or polyhalosubstituted C1-4alkyl or C1-6alkyl, for example, methyl substituted with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl, 1,1-difluoro-ethyl and the like. In case more than one halogen atoms are attached to an alkyl group within the definition of polyhaloC1-4alkyl or polyhaloC1-6alkyl, they may be the same or different.
The term heterocycle as in the definition of for instance R2 is meant to include all the possible isomeric forms of the heterocycles, for instance, pyrrolyl also includes 2H-pyrrolyl.
The hereinabove-mentioned heterocycles may be attached to the remainder of the molecule of formula (I) through any ring carbon or heteroatom as appropriate, if not otherwise specified. Thus, for example, when the 5- or 6-membered heterocycle is imidazolyl, it may be 1-imidazolyl, 2-imidazolyl, 4-imidazolyl and the like.
When any variable (eg. R4, R5 etc.) occurs more than one time in any constituent, each definition is independent.
Lines drawn into ring systems from substituents indicate that the bond may be attached to any of the suitable ring atoms of the ring system. For instance for a radical of formula (a-1), said radical may be attached to the remainder of the compound of formula (I) via a carbon atom of the phenyl moiety or via a carbon atom or heteroatom of the —B—C— moiety.
For therapeutic use, salts of the compounds of formula (I) are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxy-acetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free base form.
The compounds of formula (I) containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline, the benzathine, N-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like. Conversely the salt form can be converted by treatment with acid into the free acid form.
The term addition salt also comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
The term “quaternary amine” as used hereinbefore defines the quaternary ammonium salts which the compounds of formula (I) are able to form by reaction between a basic nitrogen of a compound of formula (I) and an appropriate quaternizing agent, such as, for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g. methyliodide or benzyliodide. Other reactants with good leaving groups may also be used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl p-toluenesulfonates. A quaternary amine has a positively charged nitrogen. Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate and acetate. The counterion of choice can be introduced using ion exchange resins.
The N-oxide forms of the present compounds are meant to comprise the compounds of formula (I) wherein one or several tertiary nitrogen atoms are oxidized to the so-called N-oxide.
The term “stereochemically isomeric forms” as used hereinbefore defines all the possible stereoisomeric forms which the compounds of formula (I), and their N-oxides, addition salts, quaternary amines or physiologically functional derivatives may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms of formula (I) and their N-oxides, salts, solvates or quaternary amines substantially free, i.e. associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers. In particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration. Compounds encompassing double bonds can have an E or Z-stereochemistry at said double bond. Stereochemically isomeric forms of the compounds of formula (I) are obviously intended to be embraced within the scope of this invention.
Some of the compounds of formula (I) may also exist in their tautomeric form (e.g. keto-enol tautomerism). Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.
Whenever used hereinafter, the term “compounds of formula (I)” is meant to also include their N-oxide forms, their salts, their quaternary amines and their stereochemically isomeric forms. Of special interest are those compounds of formula (I) which are stereochemically pure.
A first interesting embodiment of the present invention are those compounds of formula (I), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein
—CH2—CH2—CH2— (b-1);
—CH2—CH2—CH2—CH2— (b-2);
—X1—CH2—CH2—(CH2)n— (b-3);
—X1—CH2—(CH2)n—X1— (b-4);
—X1—(CH2)n′—CH═CH— (b-5);
—CH═N—X1— (b-6);
A second interesting embodiment of the present invention are those compounds of formula (I) wherein
—CH2—CH2—CH2— (b-1);
—CH2—CH2—CH2—CH2— (b-2);
—X1—CH2—CH2—(CH2)n— (b-3);
—X1—CH2—(CH2)n—X1— (b-4);
—X1—(CH2)n′—CH═CH— (b-5);
—CH═N—X1— (b-6);
A third interesting embodiment of the present invention are the compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein
A fourth interesting embodiment of the present invention are the compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R2 represents C3-7cycloalkyl; phenyl; a 4, 5, 6- or 7-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N; benzoxazolyl or a radical of formula (a-1) wherein said R2 substituent is substituted with at least one substituent selected from C1-6alkyl substituted with NR4R5; C2-6alkenyl or C2-6alkynyl, each substituted with NR4R5; polyhaloC1-6alkyl substituted with NR4R5; C1-6alkyloxy substituted with NR4R5; polyhaloC1-6alkyloxy substituted with NR4R5; or NR4R5.
A fifth interesting embodiment of the present invention are the compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R2 represents C3-7cycloalkyl or phenyl; in particular phenyl;
wherein said R2 substituent, where possible, may optionally be substituted with at least one substituent, in particular 1, 2 or 3 substituents, selected from halo; C1-6alkyl optionally substituted with at least one substituent selected from halo, hydroxy, cyano, carboxyl, NR4R5, C(═O)NR4R5, C1-4alkyloxy or C1-4alkyloxy-C1-4alkyloxy; C1-6alkyloxy; C1-6alkyloxycarbonyl; C1-4alkyloxyC1-6alkyloxy; cyano; carboxyl; C(═O)NR4R5; —S(═O)n1—R6; or arylC1-4alkyloxy.
A sixth interesting embodiment of the present invention are the compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R3 represents hydrogen;
A seventh interesting embodiment of the present invention are the compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein ring A represents phenyl or pyridyl, in particular phenyl.
An eighth interesting embodiment of the present invention are the compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein X represents a direct bond.
A ninth interesting embodiment of the present invention are the compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R1 represents hydrogen.
A tenth interesting embodiment of the present invention are the compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R2 represents an optionally substituted phenyl, in particular substituted phenyl, more in particular phenyl substituted with one substituent.
An eleventh interesting embodiment of the present invention are the compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R2 represents phenyl substituted with at least one substituent, in particular with one substituent, selected from halo; C1-6alkyl optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, C1-4alkyloxy, C1-4alkyloxyC1-4alkyloxy or NR4R5.
A twelfth interesting embodiment of the present invention are those compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein the R2 substituent is substituted with 1 substituent and preferably said substituent is placed in meta or para position.
A thirteenth interesting embodiment of the present invention are the compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R4, and R5 each independently represent hydrogen; C1-6alkylcarbonyl optionally substituted with C1-4alkyloxy; C1-6alkyloxycarbonyl; C3-7cycloalkyl-carbonyl; adamantanylcarbonyl.
A fourteenth interesting embodiment of the present invention are the compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein
Compounds of formula (I) can be prepared by reacting an intermediate of formula (II) with an intermediate of formula (III) in the presence of a suitable solvent, such as for example (CH3)2N—C(═O)H, dimethylsulfoxide, an alcohol, e.g. CH3—O—CH2—CH2—OH, 2-propanol and the like, optionally in the presence of a suitable base, such as for example N,N-diisopropylethanamine, NaH or 2,6-dimethylpyridine. The solvent is in particular dimethylsulfoxide or CH3—O—CH2—CH2—OH.
Compounds of formula (I) can also be prepared by cyclizing an intermediate of formula (IV) in the presence of a nitrite salt, such as for example NaNO2, a suitable acid, such as for example hydrochloric acid, e.g. HCl 6N or HCl 1N, and/or acetic acid and the like, and optionally in the presence of a suitable solvent, such as for example water.
The above reaction can also be used to prepare a compound of formula (I) wherein R2 represents a phenyl ring substituted with aminocarbonyl, said compound being represented by formula (I-a), from an intermediate of formula (IV) wherein R2 represents a phenyl ring substituted with an imidazole moiety, said intermediate being represented by formula (IV-a).
Compounds of formula (I) can also be prepared by reacting an intermediate of formula (V) with an intermediate of formula (III) in the presence of a suitable solvent, such as for example (CH3)2N—C(═O)H, dimethylsulfoxide, an alcohol, e.g. CH3—O—CH2—CH2—OH, 2-propanol and the like, optionally in the presence of a suitable base, such as for example N,N-diisopropylethanamine, NaH or 2,6-dimethylpyridine.
In the above reactions, the obtained compound of formula (I) can be isolated, and, if necessary, purified according to methodologies generally known in the art such as, for example, extraction, crystallization, distillation, trituration and chromatography. In case the compound of formula (I) crystallizes out, it can be isolated by filtration. Otherwise, crystallization can be caused by the addition of an appropriate solvent, such as for example water; acetonitrile; an alcohol, such as for example methanol, ethanol; and combinations of said solvents. Alternatively, the reaction mixture can also be evaporated to dryness, followed by purification of the residue by chromatography (e.g. reverse phase HPLC, flash chromatography and the like). The reaction mixture can also be purified by chromatography without previously evaporating the solvent. The compound of formula (I) can also be isolated by evaporation of the solvent followed by recrystallisation in an appropriate solvent, such as for example water; acetonitrile; an alcohol, such as for example methanol; and combinations of said solvents.
The person skilled in the art will recognise which method should be used, which solvent is the most appropriate to use or it belongs to routine experimentation to find the most suitable isolation method.
The compounds of formula (I) may further be prepared by converting compounds of formula (I) into each other according to art-known group transformation reactions.
The compounds of formula (I) may be converted to the corresponding N-oxide forms following art-known procedures for converting a trivalent nitrogen into its N-oxide form. Said N-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. t.butyl hydro-peroxide. Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
Compounds of formula (I) wherein R2 is a ring system substituted with C1-6alkyl substituted with NHC(═O)—O—C1-6alkyl, can be converted into a compound of formula (I) wherein said R2 substituent is a ring system substituted with C1-6alkyl substituted with NH2, by reaction with an acid, such as for example HCl, in the presence of a suitable solvent, such as for example dioxane and an alcohol, e.g. 2-propanol.
Compounds of formula (I) wherein R2 is a ring system substituted with halo, e.g. bromo, can be converted into a compound of formula (I) wherein said R2 substituent is unsubstituted, in the presence of H2 and in the presence of a suitable catalyst, such as for example palladium on charcoal, a suitable catalyst poison, such as for example a thiophene solution, a suitable base, such as for example N,N-diethylethanamine, and a suitable solvent, such as for example tetrahydrofuran.
Compounds of formula (I) wherein R2 is a ring system substituted with halo can also be converted into a compound of formula (I) wherein R2 is a ring system substituted with C1-6alkylthio, by reaction with a reagent of formula alkaline metal+ −S—C1-6alkyl, e.g. Na+ −S—C1-6alkyl, in the presence of a suitable solvent, such as N,N-dimethylsulfoxide. The latter compounds can further be converted into a compound of formula (I) wherein R2 is a ring system substituted with C1-6alkyl-S(═O)—, by reaction with a suitable oxidizing agent, such as a peroxide, e.g. 3-chlorobenzenecarboperoxoic acid, in the presence of a suitable solvent, such as an alcohol, e.g. ethanol.
Compounds of formula (I) wherein R2 is a ring system which is unsubstituted, can be converted into a compound wherein R2 is a ring system substituted with halo, by reaction with a suitable halogenating agent, such as, for example Br2 or 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2,2,2]octane bis[tetrafluoroborate], in the presence of a suitable solvent, such as tetrahydrofuran, water, acetonitrile, chloroform and optionally in the presence of a suitable base such as N,N-diethylethanamine.
Compounds of formula (I) wherein R2 is a ring system substituted with NH2, can be converted into a compound of formula (I) wherein R2 is a ring system substituted with NH—S(═O)2—NR4R5, by reaction with W1-S(═O)2—NR4R5 wherein W1 represents a suitable leaving group such as for example a halo atom, e.g. chloro, in the presence of a suitable solvent, such as for example N,N-dimethylacetamide and a suitable base, such as for example N,N-diethylethanamine.
Compounds of formula (I) wherein R1 is hydrogen, can be converted into a compound of formula (I) wherein R1 is ethyl by reaction with N,N-diethylethanamine in the presence of a suitable solvent, such as for example N,N-dimethylformamide.
Compounds of formula (I) wherein R2 is a ring system substituted with C(═O)—C1-6alkyl, can be converted into a compound of formula (I) wherein R2 is a ring system substituted with C(═O)—N(CH3)2, by reaction with N,N-dimethylformamide.
Some of the compounds of formula (I) and some of the intermediates in the present invention may consist of a mixture of stereochemically isomeric forms. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically.
An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase.
It is to be understood that in the above or the following preparations, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, distillation, trituration and chromatography.
Some of the intermediates and starting materials are known compounds and may be commercially available or may be prepared according to art-known procedures.
Intermediates of formula (II) can be prepared by reacting an intermediate of formula (VI) with a suitable oxidizing agent, such as for example KMnO4, in the presence of a suitable solvent, such as for example water, and a suitable acid, such as for example acetic acid. An alternative suitable oxidizing agent is meta-chloroperbenzoic acid, in a suitable solvent, such as for example a mixture of CH2Cl2 and an alcohol, e.g. methanol, or CH2Cl2 optionally in the presence of morpholinomethyl polystyrene HL resin and (polystyrylmethyl)trimethylammonium bicarbonate resin. Another suitable oxidizing agent is an aqueous solution of H2O2 in the presence of a suitable acid, such as for example acetic acid.
Intermediates of formula (II) wherein the ring system encompassed by R2 is substituted with C1-6alkyl which is substituted with NR4H, said R2 substituent being represented by —R2′—(CH2)1-6—NR4H and said intermediates being represented by formula (II-a), can be prepared by reacting an intermediate of formula (VI) wherein the ring system encompassed by R2 is substituted with C1-6alkyl which is substituted with NH2, said R2 substituent being represented by —R2′—(CH2)1-6—NH2 and said intermediate being represented by formula (VI-a), with an intermediate of formula (VII) wherein W1 represents a suitable leaving group, such as for example halo, e.g. chloro, in the presence of a suitable oxidizing agent such as for example meta-chloroperbenzoic acid, a suitable solvent, such as for example CH2Cl2 and an alcohol, e.g. methanol and the like, optionally in the presence of morpholinomethyl polystyrene HL resin and (polystyrylmethyl)trimethylammonium bicarbonate resin.
Intermediates of formula (VI) can be prepared by reacting an intermediate of formula (VIII) with a nitrite salt, such as for example NaNO2, a suitable solvent, such as for example water, and a suitable acid, such as for example hydrochloric acid 6N or 1N optionally together with acetic acid and the like.
Intermediates of formula (VI-a) can be prepared by reacting an intermediate of formula (VI-b) with a suitable acid, such as for example HCl and the like, in the presence of a suitable solvent, such as for example water.
Intermediates of formula (VI-a) can be converted into an intermediate of formula (VI) wherein the ring system encompassed by R2 is substituted with C1-6alkyl which is substituted with NH—C(═O)—O—C1-6alkyl, said R2 substituent being represented by —R2′—(CH2)1-6—NH—C(═O)—O—C1-6alkyl and said intermediates being represented by formula (VI-c), by reaction with C1-6alkyl-O—C(═O)—O—C(═O)—O—C1-6alkyl in the presence of a suitable solvent, such as for example tetrahydrofuran, and a suitable base, such as for example N,N-diethylethanamine
Intermediates of formula (VIII) can be prepared by reacting an intermediate of formula (IX) with a suitable reducing agent, such as for example H2, in the presence of a suitable catalyst, such as for example platina on charcoal or palladium on charcoal, optionally a suitable catalyst poison, such as for example a thiophene solution, a suitable solvent, such as for example N,N-dimethylacetamide, tetrahydrofuran, N,N-dimethylformamide or a suitable alcohol, such as for example methanol, or mixtures thereof, and optionally in the presence of a suitable base, such as for example N,N-diethylethanamine
Intermediates of formula (IX) can be prepared by reacting an intermediate of formula (X), wherein W2 represents a suitable leaving group, such as for example halo, in the presence of Na+ −S—CH3 in water.
Intermediates of formula (IX) can also be prepared by reacting an intermediate of formula (XI) with an intermediate of formula (XII) wherein W2 is as defined hereinabove, in the presence of Na+ −S—CH3 and a suitable solvent, such as for example N,N-dimethylformamide or a mixture of N,N-dimethylformamide and water, optionally in the presence of a suitable base, such as for example N,N-diisopropylethanamine
Intermediates of formula (XI) wherein X represents a direct bond, said intermediates being represented by formula (XI-a), can be prepared by reducing an intermediate of formula (XIII) in the presence of H2, a suitable catalyst such as for example Platina on charcoal, a suitable catalyst poison, such as for example a thiophene solution, and a suitable solvent, such as for example an alcohol, e.g. methanol. Alternatively, the reduction can be performed in the presence of Fe and an ammonium chloride solution.
Intermediates of formula (XIII) wherein the ring system encompassed by R2 is substituted with C1-6alkyl which is substituted with C1-4alkyloxyC1-4alkyloxy, said R2 substituent being represented by —R2′—(CH2)1-6—O—(CH2)1-4—O—C1-4alkyl and said intermediates being represented by formula (XIII-a), can be prepared by reacting an intermediate of formula (XIV) wherein W3 represents a suitable leaving group, such as for example halo, e.g. chloro and the like, with an intermediate of formula (XV) in the presence of a suitable base, such as for example sodium hydride.
Intermediates of formula (III) wherein R1 represents hydrogen, said intermediates being represented by formula (III-a), can be prepared by reacting an intermediate of formula (III-b) with a suitable reducing agent, such as for example H2, in the presence of a suitable catalyst, such as for example platina on charcoal or palladium on charcoal, optionally a suitable catalyst poison, such as for example a thiophene solution, a suitable solvent, such as for example N,N-dimethylacetamide, tetrahydrofuran, N,N-dimethylformamide or a suitable alcohol, such as for example methanol, and optionally in the presence of a suitable base, such as for example N,N-diethyl-ethanamine.
Intermediates of formula (IV) can be prepared by reducing an intermediate of formula (XVI) with a suitable reducing agent, such as for example H2, in the presence of a suitable catalyst, such as for example platina on charcoal or palladium on charcoal, optionally in the presence of a suitable catalyst poison, such as for example a thiophene solution, optionally in the presence of NH2—NH2, in the presence of a suitable solvent, such as for example N,N-dimethylacetamide, tetrahydrofuran, N,N-dimethylformamide or a suitable alcohol, such as for example methanol, ethanol and the like, and optionally in the presence of a suitable base, such as for example N,N-diethylethanamine.
Intermediates of formula (XVI) can be prepared by reacting an intermediate of formula (XVII) wherein W4 represents a suitable leaving group, such as for example halogen, e.g. chloro and the like, with an intermediate of formula (XI) in the presence of a suitable solvent, such as for example N,N-dimethylacetamide or an alcohol, e.g. ethanol and the like, and optionally in the presence of a suitable base, such as for example N,N-diisopropylethanamine.
Intermediates of formula (XVI) can also be prepared by reacting an intermediate of formula (XVIII) wherein W2 represents a suitable leaving group, such as defined above, with an intermediate of formula (III) in the presence of a suitable base, such as for example N,N-diisopropylethanamine or N,N-diethylethanamine, and optionally in the presence of a suitable solvent, such as for example N,N-dimethylacetamide, N,N-dimethylformamide, 1,4-dioxane.
Intermediates of formula (XVI) wherein R2—X—NH— and the
moiety represent the same substituent being represented by Ra—NH—, said intermediates being represented by formula (XVI-a), can be prepared by reacting an intermediate of formula (XII) wherein W2 is defined as herein above, with Ra—NH2 in the presence of a suitable base, such as for example N,N-diisopropylethanamine, and a suitable solvent, such as for example N,N-dimethyl-acetamide, N,N-dimethylformamide or CH2Cl2.
Intermediates of formula (XVI) can also be prepared by reacting an intermediate of formula (III) with an intermediate of formula (XI) and an intermediate of formula (XII) in the presence of a suitable solvent, such as for example N,N-dimethylformamide.
Intermediates of formula (XVII) wherein W4 represents chloro, said intermediates being represented by formula (XVII-a), can be prepared by reacting an intermediate of formula (XIX) with POCl3.
Intermediates of formula (XIX) can be prepared by reacting an intermediate of formula (III) with an intermediate of formula (XX) wherein W5 represents a suitable leaving group, such as for example halogen, e.g. chloro, in the presence of a suitable solvent, such as for example tetrahydrofuran and water, or CH3—O—(CH2)2—OH, and optionally in the presence of a suitable base, such as for example N,N-diisopropylethanamine
Intermediates of formula (XVIII) can be prepared by reacting an intermediate of formula (XI) with an intermediate of formula (XII) in the presence of a suitable solvent, such as for example N,N-dimethylacetamide, N,N-dimethylformamide, CH2Cl2 or 1,4-dioxane, and optionally in the presence of a suitable base, such as for example N,N-diisopropylethanamine
Intermediates of formula (V) can be prepared by cyclizing an intermediate of formula (XXI) in the presence of a nitrite salt, such as for example NaNO2, a suitable acid, such as for example hydrochloric acid, e.g. HCl 6N or HCl 1N, and/or acetic acid and the like, and optionally in the presence of a suitable solvent, such as for example water.
Intermediates of formula (XXI) can be prepared by reducing an intermediate of formula (XVIII) wherein W2 represents halo, said intermediate being represented by formula (XVIII-a), with a suitable reducing agent, such as for example H2, in the presence of a suitable catalyst, such as for example platina on charcoal, in the presence of a suitable catalyst poison, such as for example a thiophene solution, in the presence of a suitable solvent, such as for example N,N-dimethylacetamide, tetrahydrofuran, N,N-dimethyl-formamide or a suitable alcohol, such as for example methanol, ethanol and the like, and in the presence of a suitable base, such as for example N,N-diethylethanamine.
Intermediates of formula (XVIII-a) can be prepared by reacting an intermediate of formula (XI) with an intermediate of formula (XII) wherein W2 represents halo, said intermediate being represented by formula (XII-a), in the presence of a suitable solvent, such as for example CH2Cl2, and a suitable base, such as for example N,N-dimethylbenzenamine.
The compounds of formula (I) inhibit Glycogen synthase kinase 3 (GSK3), in particular glycogen synthase kinase 3 alpha (GSK3α) and/or glycogen synthase kinase 3 beta (GSK3β). They are selective Glycogen synthase kinase 3 inhibitors. Specific inhibitory compounds are superior therapeutic agents since they are characterized by a greater efficacy and lower toxicity by virtue of their specificity.
Synonyms for GSK3 are tau protein kinase I (TPK I), FA (Factor A) kinase, kinase FA and ATP-citrate lysase kinase (ACLK).
Glycogen synthase kinase 3 (GSK3), which exists in two isoforms as already stated above, i.e. GSK3α and GSK3β, is a proline-directed serine/threonine kinase originally identified as an enzyme that phosphorylates glycogen synthase. However, it has been demonstrated that GSK3 phosphorylates numerous proteins in vitro such as glycogen synthase, phosphatase inhibitor I-2, the type-II subunit of cAMP-dependent protein kinase, the G-subunit of phosphatase-1, ATP-citrate lyase, acetyl coenzyme A carboxylase, myelin basic protein, a microtubule-associated protein, a neurofilament protein, an N-CAM cell adhesion molecule, nerve growth factor receptor, c-Jun transcription factor, JunD transcription factor, c-Myb transcription factor, c-Myc transcription factor, L-Myc transcription factor, adenomatous polyposis coli tumor supressor protein, tau protein and β-catenin.
The above-indicated diversity of proteins which may be phosphorylated by GSK3 implies that GSK3 is implicated in numerous metabolic and regulatory processes in cells.
GSK3 inhibitors may therefore be useful in the prevention or treatment of a disease mediated through GSK3 activity such as bipolar disorder (in particular manic depression), diabetes, Alzheimer's disease, leukopenia, FTDP-17 (Fronto-temporal dementia associated with Parkinson's disease), cortico-basal degeneration, progressive supranuclear palsy, multiple system atrophy, Pick's disease, Niemann Pick's disease type C, Dementia Pugilistica, dementia with tangles only, dementia with tangles and calcification, Downs syndrome, myotonic dystrophy, Parkinsonism-dementia complex of Guam, aids related dementia, Postencephalic Parkinsonism, prion diseases with tangles, subacute sclerosing panencephalitis, frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotizing panencephalitis (SSPE) (late complication of viral infections in the central nervous system), inflammatory diseases, depression, cancer, dermatological disorders such as baldness, neuroprotection, schizophrenia, pain, in particular neuropathic pain. GSK3 inhibitors can also be used to inhibit sperm motility and can therefore be used as male contraceptives.
In particular, the compounds of the present invention are useful in the prevention or treatment of Alzheimer's disease; diabetes, in particular type 2 diabetes (non insulin dependent diabetes); bipolar disorder; cancer; pain, in particular neuropathic pain; depression; inflammatory diseases. More in particular, the compounds of the present invention are useful in the prevention or treatment of diabetes, in particular type 2 diabetes (non insulin dependent diabetes); pain, in particular neuropathic pain; depression; inflammatory diseases.
The major neuropathological landmarks in Alzheimer's disease are neuronal loss, the deposition of amyloid fibers and paired helical filaments (PHF) or neurofibrillary tangles (NFT). Tangle formation appears to be the consequence of accumulation of aberrantly phosphorylated tau protein. This aberrant phosphorylation destabilizes neuronal cytoskeleton, which leads to reduced axonal transport, deficient functioning and ultimately neuronal death. The density of neurofibrillary tangles has been shown to parallel duration and severity of Alzheimer's disease. Reduction of the degree of tau phosphorylation can provide for neuroprotection and can prevent or treat Alzheimer's disease or can slow the progression of the disease. As mentioned hereinabove, GSK3 phosphorylates tau protein. Thus compounds having an inhibitory activity for GSK3 may be useful for the prevention or the treatment of Alzheimer's disease.
Insulin regulates the synthesis of the storage polysaccharide glycogen. The rate-limiting step in the glycogen synthesis is catalyzed by the enzyme glycogen synthase. It is believed that glycogen synthase is inhibited by phosphorylation and that insulin stimulates glycogen synthase by causing a net decrease in the phosphorylation of this enzyme. Thus, in order to activate glycogen synthase, insulin must either activate phosphatases or inhibit kinases, or both.
It is believed that glycogen synthase is a substrate for glycogen synthase kinase 3 and that insulin inactivates GSK3 thereby promoting the dephosphorylation of glycogen synthase.
In addition to the role of GSK3 in insulin-induced glycogen synthesis, GSK3 may also play a role in insulin resistance. It is believed that GSK3 dependent Insulin Receptor Substrate-1 phosphorylation contributes to insulin resistance.
Therefore, GSK3 inhibition may result in the increased deposition of glycogen and a concomitant reduction of blood glucose, thus mimicking the hypoglycemic effect of insulin. GSK3 inhibition provides an alternative therapy to manage insulin resistance commonly observed in non insulin dependent diabetes mellitus and obesity. GSK3 inhibitors may thus provide a novel modality for the treatment of type 1 and type 2 diabetes.
GSK3 inhibitors may also be indicated for use in the prevention or the treatment of pain, in particular neuropathic pain.
After axotomy or chronic constriction injury, neuronal cells die through an apoptotic pathway and the morphological changes correlate with the onset of hyperalgesia and/or allodynia.
The induction of apoptosis is probably triggered by a reduced supply of neurotrophic factors as the time course of neuronal loss is positively altered by administration of neurotrophins. GSK has been shown to be involved in the initiation of the apoptotic cascade and trophic factor withdrawal stimulates the GSK3 apoptosis pathway. In view of the above, GSK3 inhibitors might reduce signals of and even prevent levels of neuropathic pain.
Due to their GSK3 inhibitory properties, the compounds of formula (I), their N-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms thereof, are useful to prevent or treat a GSK3 mediated disease, such as bipolar disorder (in particular manic depression), diabetes, Alzheimer's disease, leukopenia, FTDP-17 (Fronto-temporal dementia associated with Parkinson's disease), cortico-basal degeneration, progressive supranuclear palsy, multiple system atrophy, Pick's disease, Niemann Pick's disease type C, Dementia Pugilistica, dementia with tangles only, dementia with tangles and calcification, Downs syndrome, myotonic dystrophy, Parkinsonism-dementia complex of Guam, aids related dementia, Postencephalic Parkinsonism, prion diseases with tangles, subacute sclerosing panencephalitis, frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotizing panencephalitis (SSPE) (late complication of viral infections in the central nervous system), inflammatory diseases, depression, cancer, dermatological disorders such as baldness, neuroprotection, schizophrenia, pain, in particular neuropathic pain. The present compounds are also useful as male contraceptives. In general, the compounds of the present invention may be useful in the treatment of warm-blooded animals suffering from a disease mediated through GSK3, or they may be useful to prevent warm-blooded animals to suffer from a disease mediated through GSK3. More in particular, the compounds of the present invention may be useful in the treatment of warm-blooded animals suffering from Alzheimer's disease; diabetes, in particular type 2 diabetes; cancer; inflammatory diseases; bipolar disorder; depression; pain, in particular neuropathic pain. Even more in particular, the compounds of the present invention may be useful in the treatment of warm-blooded animals suffering from diabetes, in particular type 2 diabetes; inflammatory diseases; depression; pain, in particular neuropathic pain.
In view of the above described pharmacological properties, the compounds of formula (I) or any subgroup thereof, their N-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms, may be used as a medicine. In particular, the present compounds can be used for the manufacture of a medicament for treating or preventing a disease mediated through GSK3. More in particular, the present compounds can be used for the manufacture of a medicament for treating or preventing Alzheimer's disease; diabetes, in particular type 2 diabetes; cancer; inflammatory diseases; bipolar disorder; depression; pain, in particular neuropathic pain. Even more in particular, the present compounds can be used for the manufacture of a medicament for treating or preventing diabetes, in particular type 2 diabetes; inflammatory diseases; depression; pain, in particular neuropathic pain.
In view of the utility of the compounds of formula (I), there is provided a method of treating warm-blooded animals, including humans, suffering from or a method of preventing warm-blooded animals, including humans, to suffer from a disease mediated through GSK3, more in particular a method of treating or preventing Alzheimer's disease; diabetes, in particular type 2 diabetes; cancer; inflammatory diseases; bipolar disorder; depression; pain, in particular neuropathic pain, even more in particular diabetes, in particular type 2 diabetes; inflammatory diseases; depression; pain, in particular neuropathic pain. Said method comprises the administration, preferably oral administration, of an effective amount of a compound of formula (I), a N-oxide form, a pharmaceutically acceptable addition salt, a quaternary amine or a possible stereoisomeric form thereof, to warm-blooded animals, including humans.
The present invention also provides compositions for preventing or treating a disease mediated through GSK3, comprising a therapeutically effective amount of a compound of formula (I), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, and a pharmaceutically acceptable carrier or diluent.
The compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets.
Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. The compounds of the present invention may also be administered via inhalation or insufflation by means of methods and formulations employed in the art for administration via this way. Thus, in general the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder. Any system developed for the delivery of solutions, suspensions or dry powders via oral or nasal inhalation or insufflation are suitable for the administration of the present compounds.
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.
The present compounds are orally active compounds, and are preferably orally administered.
The exact dosage, the therapeutically effective amount and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.
When used as a medicament to prevent or treat Alzheimer's disease, the compounds of formula (I) may be used in combination with other conventional drugs used to combat Alzheimer's disease, such as galantamine, donepezil, rivastigmine or tacrine.
Thus, the present invention also relates to the combination of a compound of formula (I) and another agent capable of preventing or treating Alzheimer's disease. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I), and (b) another agent capable of preventing or treating Alzheimer's disease, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of Alzheimer's disease. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
When used as a medicament to prevent or treat type 2 diabetes, the compounds of formula (I) may be used in combination with other conventional drugs used to combat type 2 diabetes, such as glibenclamide, chlorpropamide, gliclazide, glipizide, gliquidon, tolbutamide, metformin, acarbose, miglitol, nateglinide, repaglinide, acetohexamide, glimepiride, glyburide, tolazamide, troglitazone, rosiglitazone, pioglitazone, isaglitazone.
Thus, the present invention also relates to the combination of a compound of formula (I) and another agent capable of preventing or treating type 2 diabetes. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I), and (b) another agent capable of preventing or treating type 2 diabetes, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of type 2 diabetes. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
When used as a medicament to prevent or treat cancer, the compounds of formula (I) may be used in combination with other conventional drugs used to combat cancer such as platinum coordination compounds for example cisplatin or carboplatin; taxane compounds for example paclitaxel or docetaxel; camptothecin compounds for example irinotecan or topotecan; anti-tumour vinca alkaloids for example vinblastine, vincristine or vinorelbine; anti-tumour nucleoside derivatives for example 5-fluorouracil, gemcitabine or capecitabine; nitrogen mustard or nitrosourea alkylating agents for example cyclophosphamide, chlorambucil, carmustine or lomustine; anti-tumour anthracycline derivatives for example daunorubicin, doxorubicin or idarubicin; HER2 antibodies for example trastzumab; and anti-tumour podophyllotoxin derivatives for example etoposide or teniposide; and antiestrogen agents including estrogen receptor antagonists or selective estrogen receptor modulators preferably tamoxifen, or alternatively toremifene, droloxifene, faslodex and raloxifene; aromatase inhibitors such as exemestane, anastrozole, letrazole and vorozole; differentiating agents for example retinoids, vitamin D and DNA methyl transferase inhibitors for example azacytidine; kinase inhibitors for example flavoperidol and imatinib mesylate or farnesyltransferase inhibitors for example R115777.
Thus, the present invention also relates to the combination of a compound of formula (I) and another agent capable of preventing or treating cancer. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I), and (b) another agent capable of preventing or treating cancer, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of cancer. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
When used as a medicament to prevent or treat bipolar disorder, the compounds of formula (I) may be used in combination with other conventional drugs used to combat bipolar disorder such as neuroleptica, atypical antipsychotics, anti-epileptica, benzodiazepines, lithium salts, for example olanzapine, risperidone, carbamazepine, valproate, topiramate.
Thus, the present invention also relates to the combination of a compound of formula (I) and another agent capable of preventing or treating bipolar disorder. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I), and (b) another agent capable of preventing or treating bipolar disorder, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of bipolar disorder. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
When used as a medicament to prevent or treat inflammatory diseases, the compounds of formula (I) may be used in combination with other conventional drugs used to combat inflammatory diseases such as steroids, cyclooxygenase-2 inhibitors, non-steroidal-anti-inflammatory drugs, TNF-α antibodies, such as for example acetyl salicylic acid, bufexamac, diclofenac potassium, sulindac, diclofenac sodium, ketorolac trometamol, tolmetine, ibuprofen, naproxen, naproxen sodium, tiaprofen acid, flurbiprofen, mefenamic acid, nifluminic acid, meclofenamate, indomethacin, proglumetacine, ketoprofen, nabumetone, paracetamol, piroxicam, tenoxicam, nimesulide, fenylbutazon, tramadol, beclomethasone dipropionate, betamethasone, beclamethasone, budesonide, fluticasone, mometasone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, celecoxib, rofecoxib, infliximab, leflunomide, etanercept, CPH 82, methotrexate, sulfasalazine.
Thus, the present invention also relates to the combination of a compound of formula (I) and another agent capable of preventing or treating inflammatory diseases. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I), and (b) another agent capable of preventing or treating inflammatory diseases, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of inflammatory disorders. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
When used as a medicament to prevent or treat depression, the compounds of formula (I) may be used in combination with other conventional drugs used to combat depression such as norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRI's), monoamine oxidase inhibitors (MAOI's), reversible inhibitors of monoamine oxidase (RIMA's), serotonin and noradrenaline reuptake inhibitors (SNRI's), noradrenergic and specific serotonergic antidepressants (NaSSA's), corticotropin releasing factor (CRF) antagonists, α-adrenoreceptor antagonists and atypical antidepressants.
Suitable examples of norepinephrine reuptake inhibitors include amitriptyline, clomipramine, doxepin, imipramine, trimipramine, amoxapine, desipramine, maprotiline, nortriptyline, protriptyline, reboxetine and pharmaceutically acceptable salts thereof.
Suitable examples of selective serotonin reuptake inhibitors include fluoxetine, fluvoxamine, paroxetine, sertraline and pharmaceutically acceptable salts thereof.
Suitable examples of monoamine oxidase inhibitors include isocarboxazid, phenelzine, tranylcypromine, selegiline and pharmaceutically acceptable salts thereof.
Suitable examples of reversible inhibitors of monoamine oxidase include moclobemide and pharmaceutically acceptable salts thereof.
Suitable examples of serotonin and noradrenaline reuptake inhibitors include venlafaxine and pharmaceutically acceptable salts thereof.
Suitable atypical antidepressants include bupropion, lithium, nefazodone, trazodone, viloxazine, sibutramine and pharmaceutically acceptable salts thereof.
Other suitable antidepressants include adinazolam, alaproclate, amineptine, amitriptyline/chlordiazepoxide combination, atipamezole, azamianserin, bazinaprine, befuraline, bifemelane, binodaline, bipenamol, brofaromine, bupropion, caroxazone, cericlamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, estazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprindole, levoprotiline, litoxetine, lofepramine, medifoxamine, metapramine, metralindole, mianserin, milnacipran, minaprine, mirtazapine, monirelin, nebracetam, nefopam, nialamide, nomifensine, norfluoxetine, orotirelin, oxaflozane, pinazepam, pirlindone, pizotyline, ritanserin, rolipram, sercloremine, setiptiline, sibutramine, sulbutiamine, sulpiride, teniloxazine, thozalinone, thymoliberin, tianeptine, tiflucarbine, tofenacin, tofisopam, toloxatone, tomoxetine, veralipride, viqualine, zimelidine and zometapine and pharmaceutically acceptable salts thereof, and St. John's wort herb, or Hypericum perforatum, or extracts thereof.
Thus, the present invention also relates to the combination of a compound of formula (I) and another agent capable of preventing or treating depression. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I), and (b) another agent capable of preventing or treating depression, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of depression. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
When used as a medicament to prevent or treat pain, the compounds of formula (I) may be used in combination with other conventional drugs used to combat pain such as nonsteroidal anti-inflammatory drugs (NSAIDS), centrally acting analgesics.
Suitable nonsteroidal anti-inflammatory drugs include salicylates, such as for example acetylsalicylic acid, ethenzamide, salicylamide; para-aminophenol derivatives, such as for example paracetamol, propacetamol, phenidine; anthranilates, such as for example etofenamate, flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid; arylacetic acids, such as for example acemetacin, bufexamac, diclofenac, indomethacin, lonazolac, sulindac, tolmetin, nabumetone; arylpropionic acids, such as for example flurbiprofen, ibuprofen, ketoprofen, naproxen, tiaprofenic acid; pyrazolinone derivatives, such as for example metamizol, propyphenazone; pyrazolidine-3,5-diones, such as for example kebuzone, mofebutazone, oxyphenbutazone, phenylbutazone; arylsulfonamides, such as for example isoxicam, lornoxicam, piroxicam, tenoxicam; ketorolac; oxaprozine; Cox-2 inhibitors, such as for example celecoxib, etodolac, meloxicam, nimesulfide, rofecoxib.
Suitable centrally acting analgesics include opioid agonists, such as for example morphine and morphinane derivatives, e.g. morphine, codeine, ethylmorphine, diacetylmorphine, dihydrocodeine, etorphine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone; such as for example piperidine derivatives, e.g. pethidine, ketobemidone, fentanyl, alfentanil, remifentanil, sufentanil; such as for example methadone and congeners, e.g. levomethadone, levomethadone acetate, dextromoramide, dextropropoxyphene, diphenoxylate, loperamide, piritramide; tilidine; tramadol; viminol.
Suitable centrally acting analgesics include mixed opioid agonist-antagonists and partial agonists, such as for example buprenorphine, butorphanol, dezocine, meptazinol, nalbuphine, nalorphine, pentazocine; opioid antagonists, such as for example levallorphan, naloxone, naltrexone; non-opioid compounds, such as for example carbamazepine, clonidine, flupirtine, nefopam.
Thus, the present invention also relates to the combination of a compound of formula (I) and another agent capable of preventing or treating pain. Said combination may be used as a medicine. The present invention also relates to a product containing (a) a compound of formula (I), and (b) another agent capable of preventing or treating pain, as a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of bipolar disorder. The different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
The following examples illustrate the present invention.
Hereinafter, “DMF” is defined as N,N-dimethylformamide, “DIPE” is defined as diisopropylether, “DMSO” is defined as dimethylsulfoxide, “THF” is defined as tetrahydrofuran, and “DMA” is defined as N,N-dimethylacetamide.
A mixture of 2,4-dichloro-5-nitropyrimidine (0.05 mol) in DMA (400 ml) was cooled to −20° C. and N-ethyl-N-(1-methylethyl)-2-propanamine (0.05 mol) was added, then a mixture of 3-fluoro-benzeneamine (0.05 mol) in DMA (200 ml) was added dropwise at −20° C. and the reaction mixture was stirred at −20° C. for 2 hours. The reaction mixture containing intermediate 1 was used as such in the next reaction step.
NaSCH3, 21% in H2O (0.05 mol) was added dropwise to intermediate 1 (0.05 mol) and the reaction mixture was stirred for 1.5 hours at room temperature, then the mixture was carefully poured out into H2O. The resulting precipitate was stirred over the weekend, filtered off, washed and dried (vacuum). The product was crystallised from CH3CN, then the resulting precipitate was filtered off, washed and dried (vacuum), yielding intermediate 2.
A mixture of intermediate 2 (prepared according to A1.b) (0.07 mol) and Et3N (10 g) in THF (250 ml) was hydrogenated with Pd/C, 10% (5 g) as a catalyst in the presence of a solution of thiophene in DIPE (4% v/v, 5 ml). After uptake of H2 (3 equiv), the catalyst was filtered off and the filtrate was evaporated. The residue was stirred in DIPE with a small amount of CH3CN. The precipitate was filtered off and dried. Yield: 12.3 g of intermediate 3 (70.2%). The filtrate was acidified with HCl/2-propanol while stirring. The mixture was stirred for 30 minutes. The resulting precipitate was filtered off and dried. Yield: 5.17 g of intermediate 3 (25.7%).
Intermediate 3 (0.08 mol) was dissolved in a mixture of 6N HCl (400 ml) and HOAc, p.a. (400 ml) and the whole was cooled to 0-5° C. A solution of NaNO2 (0.1 mol) in H2O (40 ml) was added dropwise over a 30 minutes period. Then, the reaction mixture was stirred for another 30 minutes while cooling on the ice-bath. Then, the mixture was stirred overnight at room temperature. The resulting precipitate was filtered off, rinsed with water, with 2-propanone, then with DIPE, and dried. Yield: 18.14 g of intermediate 4 (87%).
Intermediate 4 (15 g, 0.058 mol) was stirred in HOAc (700 ml) and cooled on an ice-bath. A solution of KMnO4, p.a. (24 g, 0.15 mol) in demineralized H2O (300 ml) was added dropwise over a 60 minutes period while cooling on an ice-bath. The mixture was stirred for one hour on the ice-bath, then for 2 hours at room temperature. Sodium bisulfite was added until a colour change resulted. EtOAc was added while stirring vigorously for a while. The mixture was stood overnight. The mixture was concentrated to ±50 ml volume. The aqueous concentrate was stirred for a while and the resulting precipitate was filtered off and dried. Yield: 11.023 g of intermediate 5 (64.8%).
A solution of 2,4-dichloro-5-nitropyrimidine (0.047 mol) in DMF (100 ml) was cooled to −50° C. and a mixture of 3-(methoxymethyl)benzenamine (0.047 mol) in DMF (50 ml) was added dropwise, then the mixture was stirred at −50° C. for 4 hours and NaSCH3 (0.1 mol) was added dropwise. The reaction mixture was stirred over the weekend at room temperature and the resulting precipitate was filtered off, washed with H2O and dried (vacuum), yielding intermediate 6.
A mixture of intermediate 6 (prepared according to A2.a) (0.029 mol) in methanol (150 ml) and THF (100 ml) was hydrogenated with Pd/C (2 g) as a catalyst in the presence of thiophene solutions (4% v/v in DIPE)(2 ml). After uptake of H2 (3 equiv., 2181 ml), the catalyst was filtered off and the filtrate was evaporated. Yield: 9 g of intermediate 7.
Intermediate 7 (prepared according to A2.b) (0.029 mol) was stirred in acetic acid, p.a. (100 ml) at room temperature and 1N HCl, p.a. (30 ml) was added, then a mixture of NaNO2 (0.03 mol) in H2O (20 ml) was added dropwise and the reaction mixture was stirred at room temperature for 1 hour. H2O (200 ml) and a saturated NaCl solution (50 ml) were added and the mixture was extracted 3 times with EtOAc. The organic layer was evaporated and the concentrate was purified over silica gel (eluent gradient: CH2Cl2/Hexane from 50/50 to 100/0). The product fractions were collected and the solvent was evaporated. Yield: 5 g intermediate 8 (60%).
A mixture of intermediate 8 (prepared according to A2.c) (0.017 mol) in CH2Cl2 (200 ml) was stirred and 3-chlorobenzenecarboperoxoic acid (0.04 mol) was added at room temperature, then the reaction mixture was stirred at room temperature and washed with a calculated NaHCO3/H2O-solution. The organic layer was dried (MgSO4), filtered off and the solvent was evaporated. The residue was crystallised from CH3CN and the resulting precipitate was filtered off and dried. Yield: 3.04 g (56%) of intermediate 9. The filtrate was evaporated and the residue was crystallised from H2O/CH3OH. The precipitate was filtered off and dried. Yield: 1.086 g of intermediate 9 (20%).
The following intermediates were prepared according to A2.d:
A mixture of intermediate
(prepared according to A2.b) (0.020 mol) in 12 N HCl, p.a. (100 ml) and H2O (demineralised) (200 ml) was stirred and refluxed for 6 hours, then the reaction mixture was stirred over the weekend at room temperature. The resulting precipitate was filtered off and dried. Yield: 3.61 g of intermediate 10 (58.5%, m.p.: >260° C.).
Intermediate
was also further reacted according to A2.d to yield
A mixture of intermediate 10 (0.005 mol) in CH2Cl2 (50 ml) was stirred at room temperature and morpholinomethyl Polystyrene HL resin (4 mmol/g) (0.020 mol; Novabiochem) was added, then a mixture of carbonochloridic acid ethyl ester (0.006 mol) in CH2Cl2 (20 ml) was added dropwise at room temperature and the reaction mixture was stirred over the weekend at room temperature. The mixture was filtered over a glass filter and the scavenger was rinsed with CH2Cl2/CH3OH (30 ml; 80/20). 3-Chlorobenzenecarboperoxoic acid (0.015 mol; 70%) was added to the filtrate and the resulting mixture was stirred overnight. Extra 3-chlorobenzenecarboperoxoic acid (1 g) was added and the mixture was stirred for another 8 hours, then PS-ammonium bicarbonate scavenger (0.045 mol; Novabiochem, 3.7 mmol/g) was added and the reaction mixture was stirred overnight at room temperature. The scavenger was filtered off and the filtrate was evaporated, yielding intermediate 11.
The following intermediates were prepared according to A3.b:
A mixture of intermediate 10 (prepared according to A3.a) (0.003 mol) and Et3N (0.0039 mol) in THF, p.a. (20 ml) was stirred at room temperature and bis(1,1-dimethylethyl)dicarbonic acid ester (0.0033 mol) was added dropwise, then the reaction mixture was stirred overnight at room temperature and the solvent was evaporated. The residue was stirred in H2O and dried. Yield: 1.100 g of intermediate 12 (100%).
A mixture of intermediate 12 (prepared according to A4.a) (0.003 mol) in CH2Cl2 (50 ml) and CH3OH (5 ml) was stirred at room temperature and then 3-chlorobenzenecarboperoxoic acid (0.006 mol, 70%) was added portionwise. The reaction mixture was stirred for 16 hours at room temperature and was washed with an equimolar aqueous NaHCO3 solution. The organic layer was separated, dried (MgSO4), filtered off and the solvent was evaporated. Yield: 1.157 g of intermediate 13 (95%).
A mixture of
(prepared according to A2.a) (0.036 mol) in Et3N (10 ml) and THF (250 ml) was hydrogenated with Pt/C5% (2 g) as a catalyst in the presence of thiophene solution (4% v/v in DIPE) (1 ml). After uptake of H2 (3 equiv.), the catalyst was filtered off and the filtrate was evaporated. The residue was taken up in a minimal amount of 2-propanone/CH3OH (9/1) and the resulting mixture was acidified with HCl/2-propanol. The mixture was stirred over the weekend and filtered, to give a filtrate and a filter residue. The filter residue was dried. Yield: 8.00 g of intermediate 14 (72%).
A mixture of intermediate 14 (prepared according to A5.a) (0.028 mol) in acetic acid, p.a. (60 ml) and 1N HCl, p.a. (20 ml) was stirred at room temperature and then a mixture of nitrous acid, sodium salt (0.030 mol) in H2O (demineralised) (20 ml) was added dropwise. The reaction mixture was stirred overnight at room temperature and was diluted with ice-water (40 ml), then filtered. The filter residue was dried, yielding intermediate 15.
A mixture of intermediate 15 (prepared according to A5.b) (0.010 mol) in CH2Cl2 (80 ml) and CH3OH (20 ml) was stirred at room temperature and 3-chlorobenzenecarboperoxoic acid (0.024 mol) was added portionwise. The reaction mixture was stirred for 3 hours at room temperature, then a mixture of NaHCO3 (0.025 mol) in H2O was added and the resulting mixture was stirred firmly. When the generation of gas was stopped, the layers were separated. The organic layer was dried (MgSO4), filtered off and the solvent was evaporated. The residue was stirred in DIPE with a small amount of CH3CN, then the precipitate was filtered off and dried. Yield: 1.218 g of intermediate 16 (39%).
The following intermediate was prepared according to A5.c:
A mixture of intermediate
(prepared according to A2.a) (0.056 mol) in THF (150 ml) and CH3OH (150 ml) was hydrogenated with Pd/C 10% (3 g) as a catalyst. After uptake of H2 (3 equivalents), the catalyst was filtered off and the filtrate was evaporated. The residue was suspended from CH3CN/H2O and then the desired product was filtered off, washed and dried (vacuum). Yield: 4.3 g of intermediate 17.
A mixture of NaNO2 (0.018 mol) in H2O (17 ml) was added dropwise to a solution of intermediate 17 (prepared according to A6.a) (0.015 mol) and 1N HCl (0.015 mol) in acetic acid (115 ml) and then the reaction mixture was stirred for a few hours at room temperature. The resulting precipitate was filtered off, washed and dried (vacuum). Yield: 3.6 g of intermediate 18.
Intermediate 18 (prepared according to A6.b) (0.0017 mol) was dissolved in acetic acid (35 ml) by heating and H2O2 (30% in H2O) (0.0044 mol) was added dropwise, then the reaction mixture was stirred overnight at 60° C. and the solvent was evaporated. The obtained residue was suspended in DIPE and a small amount of CH3CN, then the resulting precipitate was filtered off, washed and dried (vacuum). Yield: 0.350 g of intermediate 19.
The following intermediate was prepared according to A6.c:
Reaction under N2: NaH (0.07 mol) was added portionwise to 2-methoxyethanol (200 ml) cooled on an ice bath, then a solution of 1-(chloromethyl)-3-nitrobenzene (0.058 mol) in 2-methoxyethanol (q.s.) was added dropwise and the reaction mixture was stirred overnight at room temperature. The resulting precipitate was filtered off and the filtrate was evaporated, yielding intermediate 20.
A mixture of intermediate 20 (prepared according to A7.a) (0.050 mol) in CH3OH (150 ml) was hydrogenated with Pt/C5% (2 g) as a catalyst in the presence of thiophene solution (4% v/v in DIPE) (1 ml). After uptake of H2 (3 equivalents), the catalyst was filtered off and the filtrate was evaporated, yielding intermediate 21 (used as such in the next reaction step).
A solution of 2,4-dichloro-5-nitropyrimidine (0.026 mol) in DMF (70 ml) was cooled to −50° C. and then a mixture of intermediate 21 (prepared according to A7.b) (0.026 mol) in DMF (10 ml) was added dropwise. The resulting mixture was stirred for 2 hours at −40 a −30° C. and was then cooled to −50° C. NaSCH3 (0.052 mol) was added dropwise and the reaction mixture was stirred overnight at room temperature. H2O and CH3CN were added, then the resulting precipitate was filtered off, washed and dried (vacuum). Yield: 7 g of intermediate 22.
A mixture of intermediate 22 (prepared according to A7.c) (0.02 mol) in CH3OH (250 ml) was hydrogenated at 50° C. with Pd/C 10% (2 g) as a catalyst. After uptake of H2 (3 equivalents), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography on a glass filter (eluent gradient: CH2Cl2/CH3OH 99/1->98/2). The product fractions were collected and the solvent was evaporated, yielding intermediate 23 (used as such in the next reaction step).
1N HCl (0.016 mol) was added to a solution of intermediate 23 (prepared according to A7.d) (0.016 mol) in acetic acid (160 ml) and then a mixture of NaNO2 (0.018 mol) in H2O (18 ml) was added dropwise. The reaction mixture was stirred overnight at room temperature and the solvent was evaporated. The residue was purified by column chromatography on a glass filter (eluent: CH2Cl2). The product fractions were collected and the solvent was evaporated, yielding intermediate 24 (used as such in the next reaction step).
A mixture of intermediate 24 (prepared according to A7.e) (0.011 mol) and 3-chlorobenzenecarboperoxoic acid (0.022 mol) in CH2Cl2 (100 ml) was stirred overnight at room temperature and then extra 3-chlorobenzenecarboperoxoic acid (0.022 mol) was added. The reaction mixture was stirred for 4 hours at room temperature and a solution of NaHCO3 in H2O was added. The organic layer was separated, dried (MgSO4), filtered off and the solvent was evaporated. The residue was purified by column chromatography on a glass filter (eluent: CH2Cl2/CH3OH). The product fractions were collected and the solvent was evaporated. The residue was suspended in DIPE, then the desired product was filtered off, washed and dried (vacuum). Yield: 3 g of intermediate 25.
A mixture of intermediate 16 (prepared according to A5.c) (0.0002 mol) and benzenamine (0.0002 mol; 99%) in 2-methoxyethanol (1 ml) was stirred for 2 hours at 80° C. and then the reaction mixture was allowed to crystallise overnight. The resulting precipitate was filtered off and dried. Yield: 0.053 g of compound 1 (81%; melting point: 218-222° C.).
A mixture of intermediate 25 (prepared according to A7.f) (0.00028 mol) and benzenamine (0.00055 mol) in 2-methoxyethanol (2 ml) was stirred overnight at 100° C. and then H2O and CH3CN were added. After crystallisation, the resulting precipitate was filtered off and dried (vacuum). Yield: 0.0664 g of compound 2 (melting point: 143° C.).
A mixture of 5-methanesulfonyl-3-[3-(2-methoxy-ethoxy)-phenyl]-3H-[1,2,3]triazolo[4,5-d]pyrimidine (prepared according to A2.d) (0.0002 mol) and benzenamine (0.0004 mol) in 2-methoxyethanol (2 ml) was stirred for 3 hours at 100° C. and the reaction mixture was stirred overnight at room temperature. H2O and a small amount of CH3CN were added and the mixture was heated until complete dissolution and then cooled to room temperature. The resulting precipitate was filtered off, washed and dried (vacuum), yielding compound 3 (melting point: 164° C.).
A mixture of 5-(methylsulfonyl)-3-phenyl-3H-1,2,3-triazolo[4,5-d]pyrimidine (0.0005 mol) and benzenamine (0.001 mol, p.a.) in 2-methoxyethanol (3 ml, p.a.) was stirred for 2 hours at 100° C. and the reaction mixture was diluted with EtOH (3 ml). The resulting mixture was allowed to crystallise under stirring, then the resulting precipitate was filtered off and dried. Yield: 0.100 g of compound 4 (69%, melting point: 194-198° C.)
A mixture of intermediate 13 (prepared according to A4.b) (0.0003 mol) and benzenamine (0.0009 mol; 99%) in 2-methoxyethanol (3 ml) was stirred for 16 hours at 80° C., then EtOH (2 ml) was added and the reaction mixture was stirred at room temperature. The resulting precipitate was filtered off and dried. Yield: 0.082 g of compound 5 (65%, melting point: 196-198° C.).
A mixture of adamantane-1-carboxylic acid 3-(5-methanesulfonyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-benzylamide (prepared according to A3.b) (0.0002 mol) and benzenamine (0.0004 mol) in 2-methoxyethanol (2 ml) was stirred for 48 hours at 120° C. and then the crude mixture was purified by high-performance liquid chromatography. The product fractions were collected and the solvent was evaporated. The obtained residue was dissolved in EtOH and then the solvent was evaporated, yielding compound 6.
A mixture of N-[3-(5-methanesulfonyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-benzyl]-3-methyl-butyramide (prepared according to A3.b) (0.0002 mol), benzenamine (0.0004 mol) in 2-methoxyethanol (q.s.) and then the crude mixture was purified by high-performance liquid chromatography. The product fractions were collected and the solvent was evaporated (Genevac). The obtained residue was dissolved in CH3OH and then the solvent was evaporated (Genevac), yielding compound 7.
A mixture of intermediate 19 (prepared according to A6.c) (0.00024 mol) and benzenamine (0.00024 mol) in DMSO (1.5 ml) was stirred for 3 hours at 100° C., then the reaction mixture was cooled and H2O and CH3CN were added. After crystallisation, the formed precipitate was filtered off, washed and dried (vacuum). Yield: 0.024 g of compound 8 (melting point: 241° C.).
A mixture of compound 5 (prepared according to B1.e) (0.00015 mol) in 2-propanol/HCl (6M) (1 ml) and dioxane/HCl (4M) (3 ml) was stirred for 20 hours at room temperature, then the resulting precipitate was filtered off and dried.
Yield: 0.055 g of compound 9 (94%, melting point >260° C.).
Table 1 lists the compounds that were prepared according to one of the above Examples (Ex.).
The mass of the compounds was recorded with LCMS (liquid chromatography mass spectrometry). The data are gathered in Table 2 below.
The HPLC gradient was supplied by a Waters 600 system with a column heater set at 45° C. Flow from the column was split to a Waters 996 photodiode array (PDA) detector and a Waters-Micromass LCT mass spectrometer with an electrospray ionization source operated in positive ionization mode. Reversed phase HPLC was carried out on a Xterra MS C18 column (3.5 mm, 4.6×100 mm) with a flow rate of 1.6 ml/minute. Three mobile phases (mobile phase A 95% 25 mM ammoniumacetate+5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100% A to 35% B and 35% C in 3 minutes, to 50% B and 50% C in 3.5 minutes, to 100% B in 0.5 minute, 100% B for 1 minute and re-equilibrate with 100% A for 1.5 minutes. An injection volume of 10 μL was used. Mass spectra were acquired by scanning from 100 to 1200. The capillary needle voltage was 3 kV and the source temperature was maintained at 120° C. Nitrogen was used a the nebulizer gas. Cone voltage was 10 V for positive ionization mode. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
The pharmacological activity of the present compounds was examined using the following test.
GSK3beta assays were performed at room temperature in a 100 μl reaction volume of 25 mM Tris (pH 7.4) containing 10 mM MgCl2.6H2O, 1 mM DTT, 0.1 mg/ml BSA, 5% glycerol and containing 5.7 ng/μl GSK3β, 5 μM biotinylated phosphorylated CREB peptide, 1 μM ATP, 0.85 μCi/ml ATP-P33 and a suitable amount of a test compound of formula (I). After one hour, the reaction was terminated by adding 70 μl of Stop mix (0.1 mM ATP, 5 mg/ml streptavidin coated PVT SPA bead pH 11.0). The beads to which the phosphorylated CREB peptide is attached were allowed to settle overnight and the radioactivity of the beads was counted in a microtiterplate scintillation counter and compared with the results obtained in a control experiment (without the presence of a test compound) in order to determine the percentage of GSK3β inhibition. The IC50 value, i.e. the concentration (M) of the test compound at which 50% of GSK3β is inhibited, was calculated from the dose response curve obtained by performing the above-described GSK3β assay in the presence of different amounts of the test compound.
The GSK3alpha assay was performed in the same way as described above for the GSK3beta assay except for the concentration of GSK3alpha which is 0.25 ng/μl.
Table 3 lists ranges (namely pIC50>8; pIC50 ranging between 7 and 8; pIC50<7) of pIC50 values (−log IC50 (M)) obtained in the above-described test for the present compounds.
| Number | Date | Country | Kind |
|---|---|---|---|
| 05100221.0 | Jan 2005 | EP | regional |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP06/50206 | 1/13/2006 | WO | 00 | 7/13/2007 |
